VAXXITEK HVT + IBD - Field Study - France - Merial

1. FIELD STUDY IN COMMERCIAL LAYERS
WITH VAXXITEK®
HVT+IBD
FRANCE
ISABELLE DEVAUD
MERIAL AVIAN FORUM, ROMA 27TH, 28TH AND 29TH JUNE 2012VAXXITEK.COM

2. CONTEXT-ENVIRONMENT
• OBJECTIVES OF THE STUDY:
• TO COMPARE LAYING PERFORMANCE IN A
CONTROLLED, HALF-BLINDED, CONTEMPO
RARY STUDY
• COMMERCIAL BROWN PULLETS / LAYERS
• PULLET FARM + LAYER FARM (CAP. 80 000)
• 250 BIRDS PER GROUP IN THE SAME HOUSE:
• VAXXITEK HVT+IBD
• LIVE INTERMEDIATE IBD (CONTROLS)
• PRODUCTION IN 5 ENRICHED CAGES WITH 50
LAYERS EACH
MERIAL AVIAN FORUM, ROMA 27TH, 28TH AND 29TH JUNE 2012VAXXITEK.COM

3. PROTOCOL - TRIAL
GROUPS
DAY 1 0.2 ML S.C. 0.2 ML S.C.
1 DOSE BY D.W.
1 DOSE BY D.W.
EVERY 5 WEEKS
DAILY
EVERY 10 WEEKS
0.2 ML S.C.
0.2 ML S.C.
EVERY 5 WEEKS
EVERY 10 WEEKS
DAILY
WEEK 3
WEEK 4
BODY WEIGHT
EGG PRODUCTION 18 - 65 WEEKS OF AGE
EGG QUALITY
VAXXITEK HVT+IBD CONTROLS
MERIAL AVIAN FORUM, ROMA 27TH, 28TH AND 29TH JUNE 2012VAXXITEK.COM

4. RESULTS
PRODUCTION PERFORMANCES : +3.88 EGGS /HEN HOUSED
PARAMETER VAXXITEK CONTROLS P VALUE (*= SIGNIFICANT)
P < 0.001 *
P < 0.001 *
P = 0.019 *
89.07 % 87.89 %
63.77 G +/- 0.16 62.78 G +/- 0.16
38.861 N 38.049 N
AVERAGE LAYING RATE
EGG WEIGHT
GROWTH
PARAMETER VAXXITEK CONTROLS P VALUE (*= SIGNIFICANT)
BW (G) W5 89.07 % 87.89 % P >0.001
P < 0.001 *
P = 0,573
63.77 G +/- 0.16 62.78 G +/- 0.16
38.861 N 38.049 N
BW (G) W15
BW (G) W65
SHELL BREAKING
MERIAL AVIAN FORUM, ROMA 27TH, 28TH AND 29TH JUNE 2012VAXXITEK.COM

5. VAXXITEK BENEFITS*
• HIGHER PULLET WEIGHT AT POINT OF LAY
• IMPROVEMENT OF LAYING PERFORMANCE:
• + 4 EGGS / HEN HOUSED
• HIGHER AVERAGE EGG WEIGHT
• STRONGER EGG SHELL
*VAXXITEK® HVT + IBD is indicated to aid in the prevention of infectious bursal disease and Marek’s disease.
Reduction of disease may allow flocks to perform better across key production parameters. 1-4, 7-8
MERIAL AVIAN FORUM, ROMA 27TH, 28TH AND 29TH JUNE 2012VAXXITEK.COM